Please use this identifier to cite or link to this item: http://hdl.handle.net/11054/1288
Full metadata record
DC FieldValueLanguage
dc.contributorTan, Aaron C.en_US
dc.contributorChan, David L.en_US
dc.contributorFaisal, Waseken_US
dc.contributorPavlakis, Nicken_US
dc.date.accessioned2019-02-21T04:02:52Z-
dc.date.available2019-02-21T04:02:52Z-
dc.date.issued2018-
dc.identifier.govdoc01225en_US
dc.identifier.urihttp://hdl.handle.net/11054/1288-
dc.description.abstractAbstract Metastatic gastric cancer is associated with a poor prognosis and novel treatment options are desperately needed. The development of targeted therapies heralded a new era for the management of metastatic gastric cancer, however results from clinical trials of numerous targeted agents have been mixed. The advent of immune checkpoint inhibitors has yielded similar promise and results from early trials are encouraging. This review provides an overview of the systemic treatment options evaluated in metastatic gastric cancer, with a focus on recent evidence from clinical trials for targeted therapies and immune checkpoint inhibitors. The failure to identify appropriate predictive biomarkers has hampered the success of many targeted therapies in gastric cancer, and a deeper understanding of specific molecular subtypes and genomic alterations may allow for more precision in the application of novel therapies. Identifying appropriate biomarkers for patient selection is essential for future clinical trials, for the most effective use of novel agents and in combination approaches to account for growing complexity of treatment options.en_US
dc.description.provenanceSubmitted by Gemma Siemensma (gemmas@bhs.org.au) on 2019-02-06T01:25:53Z No. of bitstreams: 0en
dc.description.provenanceApproved for entry into archive by Gemma Siemensma (gemmas@bhs.org.au) on 2019-02-21T04:02:52Z (GMT) No. of bitstreams: 0en
dc.description.provenanceMade available in DSpace on 2019-02-21T04:02:52Z (GMT). No. of bitstreams: 0 Previous issue date: 2018en
dc.relation.urihttps://doi.org/10.1177/1756284818808072en_US
dc.titleNew drug developments in metastatic gastric cancer.en_US
dc.typeJournal Articleen_US
dc.type.specifiedArticleen_US
dc.bibliographicCitation.titleTherapeutic Advances in Gastroenterology.en_US
dc.bibliographicCitation.volume11en_US
dc.bibliographicCitation.stpage1en_US
dc.bibliographicCitation.endpage13en_US
dc.subject.healththesaurusGASTRIC CANCERen_US
dc.subject.healththesaurusIMMUNOTHERAPYen_US
dc.subject.healththesaurusTARGETED THERAPYen_US
Appears in Collections:Research Output

Files in This Item:
There are no files associated with this item.


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.